Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: March 23, 2023

Details for Patent: 8,980,839

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,980,839 protect, and when does it expire?

Patent 8,980,839 protects CEQUA and is included in one NDA.

This patent has eight patent family members in six countries.

Summary for Patent: 8,980,839
Title:Topical aqueous nanomicellar, ophthalmic solutions and uses thereof
Abstract: Provided herein include formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and or a polyalkoxylated alcohol and may include nanomicelles. Also include methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.
Inventor(s): Mitra; Ashim K. (Overland Park, KS), Weiss; Sidney L. (Randolph, NJ)
Assignee: Ocular Technologies SARL (Epalinges, CH)
Application Number:13/975,175
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,980,839
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound;

Drugs Protected by US Patent 8,980,839

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sun Pharm CEQUA cyclosporine SOLUTION;OPHTHALMIC 210913-001 Aug 14, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE). See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,980,839

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2013305539 See Plans and Pricing
Canada 2914472 See Plans and Pricing
Canada 3050298 See Plans and Pricing
European Patent Office 2887923 See Plans and Pricing
Hong Kong 1211867 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.